Fig. 11.

Kaplan–Meier curves for the cumulative incidence of the primer end point in the two study groups for: (a) the overall population, where we see that the study did not met its primary objective since treatment with rosuvastatin was not associated with a reduction in major adverse cardiac events (HR = 0.95, 95% CI 0.83–1.10; P = 0.516). In (b) we can see that Lymphocytes may carry a predictive information, since in the 994 patients with low percent lymphocytes (<65%) those who were treated with rosuvastatin had much longer MACE-free survival than the ones taking the placebo (HR = 0.78, 95% CI 0.61–0.99; P = 0.037). On the other hand, in (c) we see that for patients with high percent lymphocytes (>= 65%) there is no evidence of predictive information (HR = 1.08, 95% CI 0.90–1.29; P = 0.415). Note: as this is an unplanned analysis, all P values are nominal, and they have been used as descriptive measures of discrepancy and not as inferential tests of null hypotheses